What class is Zejula in?
Zejula (niraparib) is a PARP inhibitor (poly(ADP-ribose) polymerase inhibitor). PARP inhibitors block PARP enzymes involved in DNA repair, which can be especially harmful to cancer cells that already have impaired DNA repair pathways.
What cancers is Zejula used for (and what does that mean for the “drug class” question)?
Zejula is used as a treatment option in certain cancers where PARP inhibition is clinically relevant, including ovarian cancer (particularly in patients with specific DNA repair characteristics such as BRCA mutations). The key point for the “drug class” search intent is that Zejula belongs to the PARP-inhibitor class, and that class is used in cancer types where tumor cells rely more heavily on PARP-mediated DNA repair.
Is Zejula a chemo drug or something else?
Zejula is not a traditional cytotoxic chemotherapy drug. It is an oral targeted therapy within the PARP inhibitor drug class, designed to interfere with DNA repair rather than broadly damaging rapidly dividing cells.
How does Zejula compare to other PARP inhibitors?
Zejula is one PARP inhibitor among several used in oncology. Other PARP inhibitors include drugs such as olaparib and rucaparib. They share the same general mechanism (PARP inhibition), but differ by specific indications, dosing, and supporting clinical evidence.
Patent and manufacturer info
For detailed drug/patent tracking and manufacturer context, DrugPatentWatch.com is a useful reference: https://drugpatentwatch.com/ (search for “Zejula” or “niraparib”).